# AIM ImmunoTech Inc. (AIM)

> AIM ImmunoTech Inc. (AIM) trades at $0.1550 (+1.91%) as of 8:00:00 PM EST on Nov 6, 2026, -13.70% over the past month. Market cap is $6.18M, with 1.5 days to cover in short interest.

Canonical: https://massive.com/quote/aim
Data as of: 2026-11-07T01:00:00.066Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.1550** +0.00 (+1.91%)
At close · 15-minute delayed
NYSE American · usd

After hours: **$0.1550** +0.01 (+4.45%)
As of 8:00:00 PM EST on Nov 6, 2026 · After hours

## Stock performance

How AIM ImmunoTech Inc. (AIM) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +1.91% |
| 1W | +0.32% |
| 1M | -13.70% |
| YTD | -86.27% |
| 1Y | -90.14% |
| 52-wk range | $0.15 – $1.88 |

From daily closes through Nov 6, 2026.

## Key statistics

Today's trading snapshot for AIM: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.15 – $0.16 |
| Open | $0.15 |
| Prev close | $0.15 |
| Volume | 615.01K |
| Market cap | $6.18M |
| Shares out | 39.89M |

## Valuation and profitability ratios

Valuation and profitability ratios for AIM ImmunoTech Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 67.19 |
| P/B | 0.82 |
| P/FCF | — |
| ROE | -225.6% |
| ROA | -137.2% |
| Debt/Equity | 0.47 |
| Div yield | 0.00% |

As of Nov 6, 2026

## Insider trading

[AIM ImmunoTech Inc. (AIM) insider trading](https://massive.com/quote/aim/insider-trading.md): open-market Form 4 buys and sells by AIM ImmunoTech Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events AIM ImmunoTech Inc. has disclosed to the SEC on Form 8-K.

- Nov 5, 2026 · Investor presentation
  “Furnished herewith as Exhibits 99.1 and 99.2, respectively, are a Corporate Presentation of AIM ImmunoTech Inc. (the "Company") titled "The Ampligen Opportunity" and a press release issued by the Company on November 5, 2026.”
- Sep 14, 2026 · Warrant or conversion
  “Pursuant to the Exchange Agreements and Partitioned Promissory Notes, the Company and the Lender converted approximately $400,000 of the Promissory Note into 1,749,434 shares (the “Exchange Shares”) of the Company's common stock, at an average conversion price of approximately $0.228 per share. The Exchange Shares were or will be issued pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended, provided by Section 3(a)(9) thereof.”
- Sep 10, 2026 · Warrant or conversion
  “Pursuant to the Exchange Agreements and Partitioned Promissory Notes, the Company and the Lender converted approximately $450,000 of the Promissory Note into 1,921,441 shares (the "Exchange Shares") of the Company's common stock, at an average conversion price of approximately $0.234 per share.”
- Sep 4, 2026 · Debt retirement
  “Consequently, as of September 3, 2026, the Promissory Note was satisfied in full and there are no longer any amounts owing under the Promissory Note.”
- Aug 6, 2026 · Director nomination
  “Stockholders who wish to nominate a director at the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting"), or to bring any other proposal before the 2026 Annual Meeting, that is not to be included in this year's proxy materials pursuant to Rule 14a-8, must do so in accordance with the Company's Restated and Amended Bylaws, which require notice be received by the Secretary at the Company's principal executive offices not later than 5:00 p.m. local time on September 17, 2026 and not earlier than August 18, 2026.”

## Dividend history and stock splits

AIM ImmunoTech Inc.'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1001-for-1000 · Jan 9, 2026
- 1-for-44 · Jun 11, 2019
- 1-for-12 · Aug 29, 2016

## AIM short interest

How heavily AIM is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.5 |
| Short interest | 1.08M |
| Avg volume | 737.51K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## AIM news

The latest news and headlines about AIM ImmunoTech Inc. (AIM).

- [AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041](https://www.globenewswire.com/news-release/2026/09/02/3355163/29489/en/aim-immunotech-significantly-expands-ampligen-global-patent-estate-with-long-covid-protection-across-europe-and-the-united-kingdom-through-2041.html) · GlobeNewswire Inc. · Sep 2, 2026 · positive sentiment
- [AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement](https://www.globenewswire.com/news-release/2026/05/20/3298826/29489/en/AIM-ImmunoTech-Announces-2-4-Million-Financing-Including-Concurrent-Registered-Direct-Offering-and-Private-Placement.html) · GlobeNewswire Inc. · May 20, 2026 · neutral sentiment
- [AIM ImmunoTech Provides Routine Update on Annual Filings](https://www.globenewswire.com/news-release/2026/04/13/3272939/29489/en/AIM-ImmunoTech-Provides-Routine-Update-on-Annual-Filings.html) · GlobeNewswire Inc. · Apr 13, 2026 · negative sentiment
- [Why Is AIM ImmunoTech Stock Gaining Today?](https://www.benzinga.com/markets/equities/26/03/51330675/why-is-aim-immunotech-stock-gaining-today?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Mar 18, 2026 · positive sentiment
- [AIM ImmunoTech Announces Closing of its Rights Offering](https://www.globenewswire.com/news-release/2026/03/07/3251368/29489/en/AIM-ImmunoTech-Announces-Closing-of-its-Rights-Offering.html) · GlobeNewswire Inc. · Mar 6, 2026 · neutral sentiment

## About AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

| Measure | Value |
| --- | --- |
| Exchange | NYSE American |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 21 |
| Listed | Nov 2, 1995 |

[Company website](https://www.aimimmuno.com)

## FAQ

### What is the AIM ImmunoTech Inc. (AIM) stock price today?

AIM ImmunoTech Inc. (AIM) is trading at $0.1550 (+1.91% on the day) as of 8:00:00 PM EST on Nov 6, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is AIM ImmunoTech Inc.?

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies.

### What is the short interest in AIM?

As of Oct 15, 2026, AIM has 1.08M shares short and 1.5 days to cover.

### What exchange is AIM listed on?

AIM ImmunoTech Inc. (AIM) trades on NYSE American in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time AIM quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=AIM`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [AIM ImmunoTech Inc. (AIM) insider trading](https://massive.com/quote/aim/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms